News Releases

Date Title and Summary Additional Formats
Toggle Summary HTG Molecular Appoints Michelle R. Griffin to its Board of Directors
TUCSON, Ariz. , Aug. 16, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a provider of instruments, reagents, and services for molecular profiling applications, today announced the appointment of Ms. Michelle Griffin to its Board of Directors.  “We are pleased to
View HTML
Toggle Summary HTG Molecular Diagnostics Fulfills First Orders for its Next-Generation Sequencing-Based HTG EdgeSeq Precision Immuno-Oncology Panel
TUCSON, Ariz. , Aug. 15, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a provider of instruments, reagents, and services for molecular profiling applications, today announced it launched its HTG EdgeSeq Precision Immuno-Oncology Panel and has delivered its first
View HTML
Toggle Summary HTG Molecular Announces Amendment to Second Statement of Work with QIAGEN Manchester Limited
TUCSON, Ariz. , Aug. 09, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc.  (Nasdaq: HTGM) (HTG), a provider of instruments, reagents, and services for molecular profiling applications, today announced that it has entered into an amendment to the second statement of work (“SOW Two”) under
View HTML
Toggle Summary HTG Molecular Diagnostics Reports Second Quarter 2018 Results
Revenue increased 179% and 190%, respectively, compared to the three and six-month periods in the prior year                Call scheduled for today, August 7 , at 4:30 pm ET TUCSON, Ariz. , Aug. 07, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc.
View HTML
Toggle Summary HTG Molecular Diagnostics and Oncologie, Inc. Complete Master Agreement to Partner on Biomarker Development for Immuno-oncology Drug Development
TUCSON, Ariz. , Aug. 03, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a provider of instruments, reagents, and services for molecular profiling applications and Oncologie, Inc. an innovative biotechnology company with operations in Boston and Shanghai , today
View HTML
Toggle Summary HTG Molecular Diagnostics to Present at Canaccord Genuity Growth Conference
TUCSON, Ariz. , Aug. 01, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM)  (HTG), a provider of instruments, reagents, and services for molecular profiling applications, today announced TJ Johnson, Chief Executive Officer of HTG will present at the Canaccord Genuity Growth
View HTML
Toggle Summary HTG Molecular Diagnostics to Announce Second Quarter and Six Months Ended June 30, 2018 Financial Results and Host Conference Call on Tuesday, August 7
TUCSON, Ariz. , July 24, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents, and services for molecular profiling applications, today announced that it will report its financial results for the three and six months ended June 30, 2018 after
View HTML
Toggle Summary HTG Molecular Diagnostics Reports First Quarter 2018 Results
Revenue increased 203% compared to the three-month period in the prior year            Call scheduled for today, May 10 , at 4:30 pm ET TUCSON, Ariz. , May 10, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq:HTGM) (HTG), a provider of instruments, reagents and services for
View HTML
Toggle Summary HTG Molecular Diagnostics to Feature Its HTG EdgeSeq Precision Immuno-Oncology Panel at Booth #4113 at the American Society of Clinical Oncology (ASCO) Conference in June 2018
The Panel will be available to researchers as part of an early access program TUCSON, Ariz. , May 10, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq:HTGM) (HTG), a provider of instruments, reagents, and services for molecular profiling applications, today announced that it will
View HTML
Toggle Summary HTG Molecular Diagnostics and Firalis Announce an Agreement Enabling Firalis’ Commercialization of Theranostic and Research Products and Services Based on HTG EdgeSeq Technology
TUCSON, Ariz. and HUNINGUE, France , May 07, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM) (“HTG”), a provider of instruments, reagents and services for molecular profiling applications, and Firalis S.A. (“Firalis”), a provider of bioanalytical services and biomarker-based
View HTML